ストックスクリーナーアプリを入手
23.34
1.52%
0.35
アフターアワーズ：
23.34
前日終値:
$22.99
開ける：
$22.91
24時間の取引高:
443.05K
Relative Volume:
0.47
時価総額：
$1.74B
収益：
$97.36M
当期純損益:
$-172.42M
株価収益率:
-10.15
EPS:
-2.2984
ネットキャッシュフロー:
$-188.84M
1週間 パフォーマンス:
+12.16%
1か月 パフォーマンス:
+56.12%
6か月 パフォーマンス:
+101.38%
1年 パフォーマンス:
+205.10%
1日の値動き範囲:
$22.50
$23.45
1週間の範囲:
$20.48
$23.45
52週間の値動き範囲:
$7.13
$23.45
Xencor Inc Stock (XNCR) Company Profile
Compare XNCR vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
23.34 | 1.72B | 97.36M | -172.42M | -188.84M | -2.2984 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-10-29 | アップグレード | Barclays | Underweight → Overweight |
| 2025-09-17 | 再開されました | Barclays | Underweight |
| 2025-09-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-04-21 | 開始されました | William Blair | Outperform |
| 2024-12-12 | 開始されました | Wells Fargo | Overweight |
| 2024-12-02 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | 繰り返されました | BTIG Research | Buy |
| 2024-02-28 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | 開始されました | BofA Securities | Buy |
| 2022-12-06 | 開始されました | Cowen | Outperform |
| 2022-10-13 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | 開始されました | JP Morgan | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-21 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-10-15 | 再開されました | BTIG Research | Buy |
| 2021-02-24 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | 開始されました | Barclays | Underweight |
| 2020-02-25 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-01-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-11-20 | 再開されました | Guggenheim | Neutral |
| 2019-08-07 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-08-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-04-12 | 開始されました | Guggenheim | Buy |
| 2019-03-27 | 開始されました | Berenberg | Buy |
| 2019-03-15 | 開始されました | Raymond James | Outperform |
| 2018-09-10 | 再開されました | BTIG Research | Buy |
| 2018-03-28 | 再開されました | Leerink Partners | Outperform |
| 2017-03-02 | 開始されました | Instinet | Neutral |
| 2017-03-02 | 繰り返されました | Wedbush | Outperform |
| 2016-10-04 | 開始されました | Piper Jaffray | Overweight |
| 2015-12-22 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-05 | 繰り返されました | MLV & Co | Buy |
| 2015-02-12 | 繰り返されました | Oppenheimer | Outperform |
| 2015-01-28 | 繰り返されました | MLV & Co | Buy |
| 2014-07-11 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Xencor Inc (XNCR) 最新ニュース
Do Xencor’s (XNCR) Mixed 2026 Loss Trends Hint at Shifting Cost Discipline? - simplywall.st
Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR - marketbeat.com
Industry Analysts Just Made A Huge Upgrade To Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts - simplywall.st
Analysts' Revenue Estimates For Xencor, Inc. (NASDAQ:XNCR) Are Surging Higher - moomoo.com
(XNCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Biotech Stocks At 52-Week HighsBIVI +22%, XNCR, ANRO, HAE, ACAD - RTTNews
Xencor (NASDAQ:XNCR) Hits New 1-Year HighHere's What Happened - marketbeat.com
Xencor stock hits 52-week high at 21.99 USD By Investing.com - Investing.com South Africa
Xencor stock hits 52-week high at 21.99 USD - Investing.com
Xencor Inc (XNCR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Maintains Target Price $44 - moomoo.com
Analysts Are Upgrading Xencor, Inc. (NASDAQ:XNCR) After Its Latest Results - webull.com
How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit - Yahoo Finance
BofA Securities Maintains Xencor(XNCR.US) With Hold Rating, Raises Target Price to $20 - moomoo.com
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Xencor Inc (XNCR) Stock News Today - TradingKey
Xencor, Inc. Stock 12‑Month Price Target Raised to $29, Implies 45% Upside - TradingView
Xencor, Inc. (XNCR) Stock Report: A Biotech Innovator With 40.83% Upside Potential - DirectorsTalk Interviews
Barclays Reaffirms Their Buy Rating on Xencor (XNCR) - theglobeandmail.com
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages - marketbeat.com
Xencor: Q2 Earnings Snapshot - AOL.com
Cantor Fitzgerald Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $44 - moomoo.com
XENCOR Maintains Outperform Rating -- Price Target Raised to $20 - GuruFocus
Truist Financial Maintains Xencor(XNCR.US) With Buy Rating - moomoo.com
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results - The National Law Review
Wedbush Maintains Xencor(XNCR.US) With Buy Rating, Raises Target Price to $30 - Moomoo
Xencor (NASDAQ:XNCR) Surges: What Comes Next? - Kalkine Media
Does Xencor’s Mixed 2026 Loss Trend Reshape the Investment Narrative Around XNCR’s R&D Priorities? - simplywall.st
Xencor (NASDAQ:XNCR) Price Target Raised to $30.00 - MarketBeat
Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings - marketbeat.com
Wedbush Adjusts Price Target on Xencor to $30 From $26, Maintains Outperform Rating - marketscreener.com
RBC Capital Adjusts PT on Xencor to $20 From $19, Maintains Outperform Speculative Risk Rating - marketscreener.com
Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald - marketbeat.com
Xencor Inc (XNCR) SWOT Analysis: Financial Challenges and Strate - GuruFocus
Xencor Inc earnings beat by $0.51, revenue topped estimates - Investing.com
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo! Finance Canada
Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS - MarketBeat
Xencor, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
XENCOR ($XNCR) Releases Q2 2026 Earnings - Quiver Quantitative
Biopharma firm Xencor's Q2 revenue beats on royalty revenue, milestone payments - TradingView
Xencor Inc 2Q 2026: Revenue $51.22M, EPS ($0.29) — 10-Q Summary - TradingView
Xencor (NASDAQ: XNCR) nets $105M Alexion settlement as Q2 2026 loss hits $21.7M - Stock Titan
Xencor reports Q2 2026 revenue $51.2M, net loss $21.7M; cash $486.4M - TradingView
Earnings Flash (XNCR) Xencor, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $18.9M - marketscreener.com
BRIEF-Xencor Q2 EPS USD -0.29 - TradingView
Xencor, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Xencor Reports Second Quarter 2026 Financial Results - Yahoo Finance
Xencor faces earnings test after revenue miss rocks biotech By Investing.com - Investing.com Australia
Xencor faces earnings test after revenue miss rocks biotech - in.investing.com
Xencor (NASDAQ:XNCR) Trading Down 3.9%Here's Why - MarketBeat
Xencor Inc (XNCR) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):